Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (NCT07311226) titled 'A First-in-human, Single-ascending-dose Study of IBI3033 in Healthy Participants' on Dec. 16, 2025.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).
Primary Sponsor: Innovent Biologics (Suzhou) Co. Ltd.
Condition:
Healthy Participants
Intervention:
Drug: Placebo
Recruitment Status: Not recruiting
Phase: Phase 1
Date of First Enrollment: December 23, 2025
Target Sample Size: 32
Countries of Recruitment:
China
To know more, visit https://c...